JERUSALEM , March 28, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) announced today that it has filed its Annual Report on Form 20-F for the year ended December 31, 2018 , with the U.S. Securities and Exchange Commission . A copy of the Annual Report available in the Investor Relations

Conference Call Scheduled for 10am Eastern Time / 2pm Greenwich Mean Time JERUSALEM , March 27, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that it will report financial results for the fourth quarter and year ended December 31, 2018 before the market open on Thursday,

JERUSALEM , March 07, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that Mira Rosenzweig , Chief Financial Officer, will be leaving the Company in mid-April 2019 on amicable terms to pursue other professional opportunities closer to her home. Ms.

JERUSALEM , Jan. 31, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today the positive outcome of a pre-IND meeting held with the US Food and Drug Administration ( FDA ) to discuss the Company’s development plan for Oral PTH for the treatment of osteoporosis.

Entered into research collaboration and license agreement with Amgen , potential for up to $270 million in milestone payments, as well as royalties on commercial sales Met with FDA in late November 2018 to discuss clinical development plan for EB613 in the treatment of osteoporosis  Reported

JERUSALEM , Jan. 10, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX) announced today the appointment of Gerald M. Ostrov as a new independent director on its Board of Directors, effective immediately. “We are pleased to have Jerry join our Board of Directors.

Amgen will have the option to advance up to three large molecule programs using Entera’s oral delivery technology Entera will be eligible to receive up to $270 million in clinical and commercial milestone payments JERUSALEM , Dec. 11, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd.

- - - Demonstrates positive results in three metabolic parameters in patients with hypoparathyroidism treated with Oral PTH (1-34) - - - Reports a significant decrease in 24-hour urinary calcium in hypoparathyroid patients treated with Oral PTH (1-34) - - - JERUSALEM, Israel , Nov.

JERUSALEM , Oct. 02, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announced today the appointment of Faith L. Charles and Miranda J. Toledano to the company’s board of directors, effective immediately. The appointments of Ms. Charles and Ms.

JERUSALEM , Sept. 21, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) today announced the appointment of Arthur C. Santora II , MD, PhD as its new Chief Medical Officer, effective immediately. Dr. Santora has more than 30 years of experience in the biotech industry.  He has spent